Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCiStar
NCT02302157Phase 2Completed
- Sponsor
- Lineage Cell Therapeutics
- Start
- Mar 2015
- Primary completion
- Dec 2018
- Modality
- Pluripotent Stem Cells
- Countries
- 1
01
Overview
A Phase 2 trial of OPC1 in spinal cord injury (SCI), sponsored by Lineage Cell Therapeutics. Started Mar 2015; status: completed.
02
Drugs
OPC1
03
Conditions
spinal cord injury (SCI)
Beyond the preview
Go deeper on NCT02302157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02302157.